Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Pharmaceuticals, Inc. : Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

05/04/2012 | 04:05pm US/Eastern

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com. The webcast can also be accessed at the following URL: http://www.veracast.com/webcasts/baml/healthcare2012/id16635640.cfm

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the worlds established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

    CONTACTS:                         Investors:
                                      Lisa DeFrancesco
                                      (862) 261-7152

                                      Media:
                                      Charlie Mayr
                                      (862) 261-8030

(Photo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

SOURCE Watson Pharmaceuticals, Inc.

React to this article
Latest news on ACTAVIS INC
07/29DJMylan Gets European Regulator's Approval for Perrigo Deal
07/29DJMylan Gets European Regulator's Approval for Perrigo Deal
07/28 Hikma to buy Boehringer's U.S. generic drug business for $2.65 billion
07/28 Hikma to buy Boehringer's U.S. generics unit for $2.65 billion
07/27 Mylan independence from Teva's embrace comes with a price
07/27 Mylan independence from Teva's embrace comes with a price
07/27DJMylan's Leverage to Resist Teva Deal Reveals Shift in Rules
07/27 Allergan CEO, fresh off one deal, sets sights on others
07/27 Wall Street drops as China stock slump stokes growth fears
07/27DJMARKET SNAPSHOT : U.S. Stocks Follow China's Rout With 5th Straight Decline